Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bilastine + montelukast (TabQ Therapeutics)
- Development stage
- Phase 4
- Lead developer
- Prospera Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Biladay-M is a fixed-dose combination medication containing bilastine and montelukast sodium, developed and marketed by Tabq Therapeutics. Bilastine is a non-sedating, long-acting second-generation H1-antihistamine that selectively antagonizes peripheral H1 receptors to alleviate allergic symptoms such as sneezing, rhinorrhea, and ocular itching. Montelukast is a selective cysteinyl leukotriene receptor antagonist (LTRA) that blocks the CysLT1 receptor, thereby inhibiting the inflammatory effects of leukotrienes in the airways and nasal mucosa. This combination is primarily indicated for the management of allergic rhinitis, providing synergistic relief by addressing both histamine- and leukotriene-mediated pathways of the allergic response.
- Brand names
- Biladay-M
- Other names
- Bilastine and Montelukast Sodium Tablets
02
Targets
CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)HRH1 (Histamine H1 Receptor)OCT1 (Solute carrier family 22 member 1)KCNH2 (Voltage-gated potassium channel subfamily H member 2)
Beyond the preview
Go deeper on bilastine + montelukast (TabQ Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bilastine + montelukast (TabQ Therapeutics).